MCID: BRS023
MIFTS: 39

Breast Adenoid Cystic Carcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Breast Adenoid Cystic Carcinoma

Aliases & Descriptions for Breast Adenoid Cystic Carcinoma:

Name: Breast Adenoid Cystic Carcinoma 12 14
Adenoid Cystic Carcinoma of Breast 12
Adenoid Cystic Breast Carcinoma 69
Mammary Adenocystic Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4877
NCIt 47 C5130
UMLS 69 C1332167

Summaries for Breast Adenoid Cystic Carcinoma

MalaCards based summary : Breast Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma of breast, is related to bartholin's gland benign neoplasm and cardiovascular organ benign neoplasm, and has symptoms including pain An important gene associated with Breast Adenoid Cystic Carcinoma is NFIB (Nuclear Factor I B), and among its related pathways/superpathways are Gene Expression and Developmental Biology. The drugs Fentanyl and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and homeostasis/metabolism

Related Diseases for Breast Adenoid Cystic Carcinoma

Diseases related to Breast Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
id Related Disease Score Top Affiliating Genes
1 bartholin's gland benign neoplasm 10.3 ESR1 PGR
2 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
3 appendix leiomyoma 10.3 ESR1 PGR
4 bronchus adenoma 10.3 ESR1 PGR
5 glioma 10.3 ESR1 PGR
6 ovarian benign neoplasm 10.3 ESR1 PGR
7 plexiform neurofibroma 10.3 ESR1 PGR
8 marfanoid hypermobility syndrome 10.3 KIT PGR
9 paranasal sinus disease 10.3 ESR1 PGR
10 deafness, autosomal recessive 21 10.3 ESR1 PGR
11 histiocytic and dendritic cell cancer 10.2 ESR1 PGR
12 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
13 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
14 her2-receptor negative breast cancer 10.2 ESR1 PGR
15 intestinal perforation 10.2 ESR1 PGR
16 perlman syndrome 10.2 ESR1 PGR
17 skin angiosarcoma 10.2 KIT PGR
18 liver angiosarcoma 10.2 KIT PGR
19 uterine hypoplasia 10.2 KIT PGR
20 bladder adenocarcinoma 10.2 ESR1 PGR
21 triple-receptor negative breast cancer 10.2 EGFR PGR
22 skin sarcoma 10.2 EGFR PGR
23 intestinal neuroendocrine benign tumor 10.2 KIT PGR
24 precursor lymphoblastic lymphoma/leukemia 10.2 KRT7 PGR
25 x-linked leigh syndrome 10.2 AR ESR1
26 ulceroglandular tularemia 10.2 AR ESR1
27 nonossifying fibromyxoid tumor 10.2 KIT KRT7
28 colon signet ring adenocarcinoma 10.2 AR KIT
29 synovitis 10.2 ESR1 KRT7
30 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
31 adenoiditis 10.2
32 vaginal adenosarcoma 10.2 ESR1 PGR
33 intraneural perineurioma 10.2 ESR1 PGR
34 atypical lipomatous tumor 10.2 ESR1 KIT PGR
35 rectal neoplasm 10.2 ESR1 KIT PGR
36 postpartum depression 10.2 ESR1 KIT PGR
37 mucoepidermoid thyroid carcinoma 10.2 KRT5 PGR
38 biemond syndrome 10.2 KRT7 PGR
39 pilar sheath acanthoma 10.2 ESR1 KIT PGR
40 arthus reaction 10.2 ESR1 KIT PGR
41 kidney clear cell sarcoma 10.2 EGFR KIT NFIB
42 gangliosidosis gm1 10.2 ESR1 KIT PGR
43 heel spur 10.2 AR KRT7
44 glycerol kinase deficiency, adult form 10.1 ESR1 KIT PGR
45 main bronchus cancer 10.1 KRT7 PGR
46 laryngeal neuroendocrine tumor 10.1 AR KIT PGR
47 agenesis and aplasia of uterine body 10.1 EGFR KRT7
48 proteus-like syndrome 10.1 KRT7 KRT8
49 precursor t-lymphoblastic lymphoma/leukemia 10.1 EGFR KIT
50 envenomization by bothrops lanceolatus 10.1 KRT7 KRT8

Graphical network of the top 20 diseases related to Breast Adenoid Cystic Carcinoma:



Diseases related to Breast Adenoid Cystic Carcinoma

Symptoms & Phenotypes for Breast Adenoid Cystic Carcinoma

UMLS symptoms related to Breast Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.77 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.77 KRT5
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.77 KRT5 KRT8
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.77 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.77 KRT8
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.77 KRT7
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.77 KRT5 KRT7 KRT8
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.77 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.77 KRT5 KRT7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.36 KRT8
11 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.36 KRT7 KRT8 TOP2A
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.36 TOP2A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.36 KRT7 KRT8
14 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.36 TOP2A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.36 KRT8
16 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.36 KRT7 KRT8

MGI Mouse Phenotypes related to Breast Adenoid Cystic Carcinoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.09 AR EGFR ESR1 EZH2 KIT KRT7
2 cardiovascular system MP:0005385 10.08 AR EGFR ESR1 EZH2 KIT KRT8
3 growth/size/body region MP:0005378 10.06 NFIB AR EGFR ESR1 EZH2 KIT
4 digestive/alimentary MP:0005381 10.05 AR EGFR ESR1 KIT KRT5 KRT8
5 embryo MP:0005380 10.04 AR EGFR ESR1 EZH2 KIT KRT8
6 endocrine/exocrine gland MP:0005379 10.02 AR EGFR ESR1 EZH2 KIT NFIB
7 mortality/aging MP:0010768 9.97 AR EGFR ESR1 EZH2 KIT KRT5
8 integument MP:0010771 9.95 ESR1 EZH2 KIT KRT5 PGR AR
9 craniofacial MP:0005382 9.92 AR EGFR KIT KRT5 NFIB
10 limbs/digits/tail MP:0005371 9.85 AR EGFR ESR1 KIT KRT5 PGR
11 muscle MP:0005369 9.73 EGFR ESR1 EZH2 KIT PGR AR
12 neoplasm MP:0002006 9.63 AR EGFR ESR1 EZH2 KIT PGR
13 no phenotypic analysis MP:0003012 9.43 EGFR ESR1 EZH2 KIT KRT5 PGR
14 normal MP:0002873 9.1 AR EGFR ESR1 EZH2 KIT PGR

Drugs & Therapeutics for Breast Adenoid Cystic Carcinoma

Drugs for Breast Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
3 Liver Extracts Phase 3,Phase 2,Phase 1
4 Adjuvants, Anesthesia Phase 3
5 Analgesics Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, General Phase 3
9 Anesthetics, Intravenous Phase 3
10 Central Nervous System Depressants Phase 3
11 Narcotics Phase 3
12 pancreatic polypeptide Phase 3,Phase 1
13 Peripheral Nervous System Agents Phase 3
14 Antimitotic Agents Phase 3,Phase 2,Phase 1
15 Cola Nutraceutical Phase 3,Phase 2,Phase 1
16
Indinavir Approved Phase 2 150378-17-9 5362440
17
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
18
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
19 Anti-HIV Agents Phase 2
20 Anti-Infective Agents Phase 2,Phase 1
21 Anti-Retroviral Agents Phase 2
22 Antiviral Agents Phase 2,Phase 1
23 Cytochrome P-450 CYP3A Inhibitors Phase 2
24 Cytochrome P-450 Enzyme Inhibitors Phase 2
25 HIV Protease Inhibitors Phase 2
26
protease inhibitors Phase 2
27 Immunosuppressive Agents Phase 2,Phase 1
28 Androgens Phase 1, Phase 2
29 Antimetabolites Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 2,Phase 1
31 Imatinib Mesylate Phase 2 123596
32 Protein Kinase Inhibitors Phase 2,Phase 1
33 Fluorides Phase 1, Phase 2
34 Fluorodeoxyglucose F18 Phase 1, Phase 2
35 Radiopharmaceuticals Phase 1, Phase 2
36
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
37
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
38
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
39
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
40
Pemetrexed Approved, Investigational Phase 1 150399-23-8, 137281-23-3 446556 60843
41
Lenograstim Approved Phase 1 135968-09-1
42
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
43
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
44
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
46
leucovorin Approved, Nutraceutical Phase 1 58-05-9 54575, 6560146 143
47
7-hydroxystaurosporine Experimental Phase 1 112953-11-4 72271
48
Camptothecin Experimental Phase 1 7689-03-4
49 Staurosporine Experimental Phase 1 62996-74-1
50
tipifarnib Investigational Phase 1 192185-72-1 159324

Interventional clinical trials:

(show all 29)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
4 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
5 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
6 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
7 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
8 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
9 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
10 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1
11 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
12 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
13 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
14 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1
15 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
16 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
17 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1
18 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1
19 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
20 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
21 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1
22 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1
23 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
24 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
25 Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema Completed NCT00828516
26 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
27 Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer Completed NCT00002520
28 Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 Active, not recruiting NCT01015963
29 Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor Terminated NCT01096381

Search NIH Clinical Center for Breast Adenoid Cystic Carcinoma

Genetic Tests for Breast Adenoid Cystic Carcinoma

Anatomical Context for Breast Adenoid Cystic Carcinoma

MalaCards organs/tissues related to Breast Adenoid Cystic Carcinoma:

39
Breast

Publications for Breast Adenoid Cystic Carcinoma

Articles related to Breast Adenoid Cystic Carcinoma:

id Title Authors Year
1
Cutaneous Metastasis of Breast Adenoid Cystic Carcinoma to the Scalp. ( 26968987 )
2016
2
18F-FDG PET/CT Imaging of Bilateral Renal Metastasis of Breast Adenoid Cystic Carcinoma. ( 26562575 )
2015
3
Breast adenoid cystic carcinoma in a 19-year-old man: a case report and review of the literature. ( 25885366 )
2015
4
Male breast adenoid cystic carcinoma. ( 24403896 )
2013
5
Clinical review--breast adenoid cystic carcinoma. ( 22154460 )
2012

Variations for Breast Adenoid Cystic Carcinoma

Cosmic variations for Breast Adenoid Cystic Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM25159 PTEN breast,NS,carcinoma,adenoid cystic carcinoma c.254-3C>T p.? 12
2 COSM27376 PIK3CA breast,NS,carcinoma,adenoid cystic carcinoma c.93A>G p.I31M 12
3 COSM476 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1799T>A p.V600E 12
4 COSM449 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1391G>A p.G464E 12
5 COSM467 BRAF breast,NS,carcinoma,adenoid cystic carcinoma c.1781A>G p.D594G 12

Expression for Breast Adenoid Cystic Carcinoma

Search GEO for disease gene expression data for Breast Adenoid Cystic Carcinoma.

Pathways for Breast Adenoid Cystic Carcinoma

Pathways related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 AR EGFR ESR1 EZH2 KIT NFIB
2
Show member pathways
13.09 EGFR EZH2 KIT KRT5 KRT7 KRT8
3
Show member pathways
12.51 AR EGFR ESR1 KIT PGR
4 11.8 AR EGFR ESR1
5
Show member pathways
11.58 KRT5 KRT7 KRT8
6
Show member pathways
11.53 EGFR ESR1 PGR
7
Show member pathways
11.3 EGFR ESR1 KIT
8
Show member pathways
11.09 AR ESR1 PGR
9
Show member pathways
10.46 AR ESR1 NFIB

GO Terms for Breast Adenoid Cystic Carcinoma

Cellular components related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.85 AR EGFR ESR1 EZH2 KRT5 KRT7
2 cytoplasm GO:0005737 9.65 AR EGFR ESR1 EZH2 KIT KRT5
3 nuclear chromatin GO:0000790 9.5 AR ESR1 EZH2
4 intermediate filament GO:0005882 9.43 KRT5 KRT7 KRT8
5 keratin filament GO:0045095 8.8 KRT5 KRT7 KRT8

Biological processes related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.73 KRT5 KRT7 KRT8
2 regulation of transcription from RNA polymerase II promoter GO:0006357 9.72 AR EGFR ESR1 EZH2 KIT
3 negative regulation of gene expression GO:0010629 9.71 ESR1 EZH2 PGR
4 transcription initiation from RNA polymerase II promoter GO:0006367 9.7 AR ESR1 PGR
5 cornification GO:0070268 9.67 KRT5 KRT7 KRT8
6 male gonad development GO:0008584 9.65 AR ESR1 KIT
7 response to estradiol GO:0032355 9.63 EGFR ESR1 EZH2
8 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.63 AR EGFR ESR1 NFIB PGR TOP2A
9 stem cell differentiation GO:0048863 9.57 ESR1 KIT
10 positive regulation of phosphorylation GO:0042327 9.55 AR EGFR
11 steroid hormone mediated signaling pathway GO:0043401 9.54 AR ESR1 PGR
12 mammary gland alveolus development GO:0060749 9.51 AR ESR1
13 protein localization to chromatin GO:0071168 9.43 ESR1 EZH2
14 positive regulation of MAP kinase activity GO:0043406 9.43 EGFR EZH2 KIT
15 positive regulation of phospholipase C activity GO:0010863 9.4 ESR1 KIT
16 morphogenesis of an epithelial fold GO:0060571 8.96 AR EGFR
17 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 8.62 AR PGR

Molecular functions related to Breast Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.78 AR ESR1 NFIB PGR
2 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.71 AR ESR1 NFIB PGR
3 ATPase binding GO:0051117 9.61 AR ESR1 PGR
4 chromatin binding GO:0003682 9.55 AR EGFR ESR1 EZH2 TOP2A
5 steroid hormone receptor activity GO:0003707 9.5 AR ESR1 PGR
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.46 EGFR KIT
7 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.43 AR ESR1 PGR
8 nitric-oxide synthase regulator activity GO:0030235 9.37 EGFR ESR1
9 enzyme binding GO:0019899 9.35 AR EGFR ESR1 PGR TOP2A
10 steroid binding GO:0005496 8.8 AR ESR1 PGR

Sources for Breast Adenoid Cystic Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....